Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

BIOmarker based diagnostic TOOLkit to personalize pharmacological approaches in congestive heart failure

Project description

Paving the way for more efficient heart failure treatment and management

In Europe, 6.5 million people battle chronic heart failure (HF), the leading cause of adult hospitalisation with a 5-year mortality rate of 70 %. Current diagnostics for HF are inadequate, leading to ineffective use of diuretics, a cornerstone for symptom relief. The EU-funded BIOTOOL-CHF project aims to revolutionise care with validated biomarkers, an AI-based congestion and prognosis predictor, a decision-making tool for diuretic management and a point-of-care diagnostic. This approach promises to usher in a new era of personalised HF management, optimising existing pharmaceuticals and reducing re-hospitalisations. This innovative approach not only transforms HF management but also sets the stage for personalised strategies in treating HF with reduced ejection fraction.

Objective

Heart failure (HF) is a chronic clinical condition involving up to 6.5 million people in Europe, the most frequent cause of hospitalization in adults with a 5-year mortality rate up to 70%. Several drugs positively modify the course of disease in the patients with HF with reduced ejection fraction (HFrEF), with a high level of evidence. Besides, the use of diuretics, the basic cornerstone of symptoms relief in HFrEF by targeting congestion, is supported by poor and outdated evidence.

Congestion drives symptoms worsening leading to hospital admission. Clinical evaluation of congestion is often inaccurate and insensitive to detect interstitial or intravascular fluid overload, and thus insufficient to guide use of diuretics. Indeed, their use is inefficient, with studies showing that up to 70% of patients with chronic HFrEF show congestion despite diuretic therapy, the use of diuretics does prevent clinical events in patients discharged after an acute heart failure episode, and diuretics may represent a barrier to adherence to disease modifier therapies. An appropriate management of diuretic therapy is therefore crucial to overcome the risk of re-hospitalisation, manage patients symptoms, and achieve target guideline-directed medical therapy.

To fill these gaps, BIOTOOL-CHF will 1) validate a set of qualified biomarkers estimating congestion, 2) define a multiparametric artificial intelligence-based score predicting congestion and prognosis, 3) develop a decision-making tool to manage congestion by diuretics, 4) develop a Point of Care companion diagnostic (CD) to assess biomarkers concentrations 5) set up a Strategy plan for industrial development and market access of the CD. This approach will support the definition of a framework to regulatory agencies and scientific societies to disseminate recommendations for a more efficient use of existing pharmaceuticals and allow a personalised strategy for the management of HFrEF, by using new tools and digital solutions.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2022-TOOL-11

See all projects funded under this call

Coordinator

IRCCS AZIENDA OSPEDALIERO- UNIVERSITARIA DI BOLOGNA
Net EU contribution
€ 1 438 450,00
Address
VIA ALBERTONI 15
40138 Bologna
Italy
Region
Nord-Est Emilia-Romagna Bologna
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Links
Total cost
€ 1 438 450,00

Participants (23)

Partners (1)